A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
NCT ID: NCT06710431
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
36 participants
INTERVENTIONAL
2025-10-01
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AFA-281 placebo control
AFA-281 placebo control group
AFA-281
AFA-281
Low dose of AFA-281
AFA-281 at 60 mg per day
AFA-281
AFA-281
High dose AFA-281
AFA-281 at 120 mg per day
AFA-281
AFA-281
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AFA-281
AFA-281
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
3. Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for moderate or severe AUD
4. Report drinking at least 28 drinks per week if male, 21 drinks per week if female, in the 28 days prior to consent.
5. Must be surgically sterile (vasectomy, tubal ligation, or hysterectomy) or agree to be sexually inactive or agree to use a barrier method of birth control (i.e., condom) from the start of screening until study completion, and agree to refrain from donating sperm for 90 days after study drug administration.
Exclusion Criteria
2. Current (last 12 months) DSM-5 diagnosis of dependence on any psychoactive substances other than nicotine
3. Current DSM-5 diagnosis of substance use disorder for any substance other than alcohol and nicotine
4. Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
5. Current DSM-5 major depressive disorder with suicidal ideation
6. Positive urine screen for narcotics, amphetamines, or sedative hypnotics
7. Clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
8. Pregnancy, nursing, or refusal to use reliable method of birth control if female
9. History of significant sensitivity to any drug.
10. Has a clinically significant abnormal ECG or an ECG with a QTc interval corrected for heart rate using the Fridericia formula (QTcF) \> 430 ms.
11. History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, endocrine, dermatological, metabolic or psychiatric disease or disorder, or any uncontrolled medical illness.
12. Has an estimated creatinine clearance (CrCl) outside of normal range.
13. History of head trauma with loss of consciousness, seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.
14. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption.
15. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site.
16. Liver enzymes AST, ALT, or GGT ≥ 3 times upper normal limit.
17. Positive urine drug screen for drugs of abuse at Screening or Day -1.
18. Receipt of any drug by injection within 30 days prior to study drug administration.
19. A clinically notable vital sign abnormality including a history of syncopal or near syncopal events following abrupt change in posture.
20. Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration.
21. Pregnant or nursing women.
22. Receipt of any investigational products within 6 weeks prior to study drug administration.
23. Current enrollment in another clinical study.
24. Previous enrollment in this study.
25. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to participate in the AFA-281 Phase I1a Study.
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Afasci Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lara Ray, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lara Ray, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFA-281-304
Identifier Type: -
Identifier Source: org_study_id